Trial reportWorld journal of gastroenterology2012
Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Trial report in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 22 citations in OpenAlex.
- Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Trial
- Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-LineMicroorganisms · 2025Review
- Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness.Scientific reports · 2021Article
- Optimization Strategies Aimed to Increase the Efficacy ofMolecules (Basel, Switzerland) · 2020Review
- Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication ofGastroenterology research and practice · 2017Article
- The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.Bosnian journal of basic medical sciences · 2015Article
- New transport medium for cultural recovery of Helicobacter pylori.Journal of clinical microbiology · 2014Article
- Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.World journal of gastroenterology · 2014Review
- Therapy of Helicobacter pylori: present medley and future prospective.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare triple therapy vs quadruple therapy for 10 d as first-line treatment of Helicobacter pylori (H. pylori) infection.
methodsConsecutive H. pylori positive patients never treated in the past for this infection were randomly treated with triple therapy of pantoprazole (PAN) 20 mg bid, amoxicillin (AMO) 1 g bid and moxifloxacin (MOX) 400 mg bid for 10 d (PAM) or with quadruple therapy of PAN 20 mg bid, AMO 1 g bid, MOX 400 mg bid and bismuth subcitrate 240 mg bid for 10 d (PAMB). All patients were found positive at 13 C-Urea breath test (UBT) performed within ten days prior to the start of the study. A successful outcome was confirmed with an UBT performed 8 wk after the end of treatment. χ(2) analysis was used for statistical comparison. Per protocol (PP) and intention-to-treat (ITT) values were also calculated.
resultsFifty-seven patients were enrolled in the PAM group and 50 in the PAMB group. One patient in each group did not return for further assessment. Eradication was higher in the PAMB group (negative: 46 and positive: 3) vs the PAM group (negative: 44 and positive: 12). The H. pylori eradication rate was statistically significantly higher in the PAMB group vs the PAM group, both with the PP and ITT analyses (PP: PAMB 93.8%, PAM 78.5%, P < 0.02; ITT: PAMB 92%, PAM 77.1 %, P <0.03).
conclusionThe addition of bismuth subcitrate can be considered a valuable adjuvant to triple therapy in those areas where H. pylori shows a high resistance to fluoroquinolones.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.